A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity

被引:75
|
作者
DeLuca, A
MacLachlan, TK
Bagella, L
Dean, C
Howard, CM
Claudio, PP
Baldi, A
Khalili, K
Giordano, A
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL,PHILADELPHIA,PA 19107
[2] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19107
[3] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107
[4] THOMAS JEFFERSON UNIV,JEFFERSON INST MOL MED,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107
关键词
D O I
10.1074/jbc.272.34.20971
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Cdk2 kinase has long been known to be involved in the progression of mammalian cells past the G(1) phase restriction point and through DNA replication in the cell cycle. The Rb family of proteins, consisting of pRb, p107, and pRb2/p130, has also been shown to monitor progression of G, phase, mostly through their interaction with E2F family members. p107 is able to inhibit Cdk2 kinase activity through this interaction via a p21-related domain present in the C terminus of the protein. We show here that pRb2/p130 also possesses this activity, but through a separate domain. Moreover, we correlate the increased expression of pRb2/p130 during various cellular processes with the decreased kinase activity of Cdk2. We hypothesize that pRb2/p130 may act not only to bind and modify E2F activity, but also to inhibit Cdk2 kinase activity in concert with p21 in a manner different from p107.
引用
收藏
页码:20971 / 20974
页数:4
相关论文
共 50 条
  • [21] Clinicopathological significance of pRb2/p130 expression in squamous cell carcinoma of the esophagus
    Tadahiro Nozoe
    Daisuke Korenaga
    Shuhei Itoh
    Motonori Futatsugi
    Yoshihiko Maehara
    Journal of Cancer Research and Clinical Oncology, 2002, 128 : 691 - 696
  • [22] 人体肺癌组织内pRb2/p130的表达及意义
    郑素勤
    王利民
    孙瑞军
    张玉强
    荣玲
    王献华
    杨秋
    中国综合临床, 2002, (09) : 61 - 62
  • [23] Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo
    Howard, CM
    Claudio, PP
    Gallia, GL
    Gordon, J
    Giordano, GG
    Hauck, WW
    Khalili, K
    Giordano, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) : 1451 - 1460
  • [24] 人体正常组织内pRb2/p130的表达及意义
    郑素勤
    孙瑞军
    张玉强
    荣玲
    王献华
    王利民
    华北煤炭医学院学报, 2002, (05) : 550 - 552
  • [25] Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer
    Caputi, M
    Groeger, AM
    Esposito, V
    De Luca, A
    Masciullo, V
    Mancini, A
    Baldi, F
    Wolner, E
    Giordano, A
    CLINICAL CANCER RESEARCH, 2002, 8 (12) : 3850 - 3856
  • [27] Functional analysis of pRb2/p130 and Cdk9: implications in cancer, viral pathogenesis, drug development and gene therapy
    Romano, Gaetano
    Giordano, Antonio
    JOURNAL OF NEUROVIROLOGY, 2010, 16 : 74 - 74
  • [28] pRb2/p130 and VEGF expressions in endometrial carcinoma in relation to angiogenesis and tumor histopathologic grade
    Sanseverino, F.
    Torricelli, M.
    Leoncini, L.
    Claudio, P. P.
    Scambia, G.
    Giordano, A.
    Petraglia, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (04) : 947 - 947
  • [29] 子宫内膜癌中pRb2/p130的表达及意义
    支霜
    傅芬
    江西医学院学报, 2009, 49 (06) : 22 - 24
  • [30] pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade
    Sanseverino, F
    Santopietro, R
    Torricelli, M
    D'Andrilli, G
    Russo, G
    Cevenini, G
    Bovicelli, A
    Leoncini, L
    Scambia, G
    Petraglia, F
    Claudio, PP
    Giordano, A
    CANCER BIOLOGY & THERAPY, 2006, 5 (01) : 84 - 88